The primary objective of the Biostatistics Core is to contribute to the science and operation of the program project by participating fully in its activities as it has for the preparation of this application. This includes assistance and direction in experimental design, quality control, data collection and management, and statistical data analysis through consultation and collaboration. The team that helps prepare the application and will provide biostatistical supports for this program project consists of the following statisticians from the University of Minnesota and the Masonic Cancer Center: Chap Le (Core Director), Xianghua Luo (core Co- Director), Todd DeFor, and Yen-Yi Ho, an expert in Biostatistics and in Computational Biology. For the A1 revised application, Dr. Koopmeiners has been added for his expertise in trial monitoring and adaptive design. This team is strengthened with the addition of the team from Tao Wang, a statistical geneticist from the Medical College of Wisconsin and CIBMTR. Dr. Wang will contribute to provide statistical supports for Projects 1 and 3. The assignment of biostatistician support is logical and based on whether the data is collected and stored at the University of Minnesota or transplant data through the National Marrow Donor Program and the CIBMTR at the Medical College of Wisconsin.
The primary objective of the Biostatistics Core B is to contribute to the science and operation of the program project by participating fully in its activities as it has for the preparation of this application. This includes assistance and direction in experimental design, quality control, data collection and management, and statistical data analysis through consultation and collaboration.
|Grzywacz, Bartosz; Moench, Laura; McKenna Jr, David et al. (2018) Natural Killer Cell Homing and Persistence in the Bone Marrow After Adoptive Immunotherapy Correlates With Better Leukemia Control. J Immunother :|
|Sarhan, Dhifaf; Hippen, Keli L; Lemire, Amanda et al. (2018) Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37. Cancer Immunol Res 6:766-775|
|Williams, Robin L; Cooley, Sarah; Bachanova, Veronika et al. (2018) Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells. Biol Blood Marrow Transplant 24:618-622|
|Don Yun, Hyun; Felices, Martin; Vallera, Daniel A et al. (2018) Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells. Blood Adv 2:1580-1584|
|Cooley, Sarah; Parham, Peter; Miller, Jeffrey S (2018) Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation. Blood 131:1053-1062|
|Williams, Shelly M; Sumstad, Darin; Kadidlo, Diane et al. (2018) Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution. Transfusion 58:1458-1467|
|Romee, Rizwan; Cooley, Sarah; Berrien-Elliott, Melissa M et al. (2018) First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood 131:2515-2527|
|Oh, Felix; Todhunter, Deborah; Taras, Elizabeth et al. (2018) Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin. Clin Pharmacol 10:113-121|
|Rashidi, Armin; Ebadi, Maryam; Said, Bassil et al. (2018) Absence of early HHV-6 reactivation after cord blood allograft predicts powerful graft-versus-tumor effect. Am J Hematol :|
|Bachanova, Veronika; Sarhan, Dhifaf; DeFor, Todd E et al. (2018) Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer Immunol Immunother 67:483-494|
Showing the most recent 10 out of 108 publications